In Spain and Portugal 8,000 cases of metastatic cancer are diagnosed each year, and it claimed the lives of 6,600 women in Spain in 2020 alone. To improve these results, the Palex Group has signed a collaboration agreement with Biovica, a Swedish biotechnological company specialised in non-invasive cancer monitoring to introduce the DiviTum® TKa test in Spain and Portugal.

This is a non-invasive test performed on blood samples that allows the evolution of advanced breast cancer in women treated with cyclin inhibitors 4/6 (CDK4/6i) to be predicted, reducing the time required to establish the effectiveness of the treatment received by the patient from several months to just two weeks.

"Making timely therapeutic decisions is vital to optimising patient treatment and increasing their survival chances, for which reason being able to call on new non-invasive tools capable of personalising treatment with high-impact drugs like CDK4/6i is a revolutionary opportunity," said Carlos Hagen, Medical Director of Oncology at Palex.

Thanks to the agreement between Palex and Biovica, Spain will be the eighth European country to have this test. "Our support of DiviTum TKa is proof of our firm desire to offer health professionals and their patients disruptive solutions capable of improving people's lives, in this case with a non-invasive solution that facilitates a prognosis and monitoring of patients with advanced cancer treated with CDK4/6i to ascertain this treatment's effectiveness," said Xavier Carbonell, CEO of the Palex Group.

"The Palex Group has a proven history of marketing precise medical solutions for breast cancer, with impressive results. We're delighted to be able to sign an agreement with such a successful and dynamic team. This agreement sets out a strategic sales focus for the DiviTum TKa test in the Spanish and Portuguese markets," said Helle Fisker, Vice-President of Marketing at Biovica.

Palex will lead the rollout and implementation of DiviTum TKa, focusing its efforts on generating a high level of awareness and knowledge among breast oncologists and other relevant decision makers, and it will include the test in clinical guides thanks to its differential value for professionals and patients.

For more information about Palex, visit www.palexhealth.com.